top of page
Western Arthur Range Tasmania.jpeg

Protect. Then Grow.

Financial Repression means a different investing climate

Writer's picture: Chester Asset ManagementChester Asset Management

Updated: May 5, 2022

The most recent COVID inspired emergency response has seen 20 years of US central bank debt accumulation double in 12 months. It is very unclear how this ever gets repaid. We have arrived at a juncture of financial repression, for governments themselves can not afford materially higher interest rates, but are effectively forced to run budget deficits, for the greater good.


The control of the supply of money is changing from central banks to governments as they grapple with the moral hazard of looking after their citizens’ way of life. The consequence of this appears to be that short term interest rates will not reflect inflation expectations and any sign of significant asset price volatility will see the effective capping of long term interest rates.


This line of thinking outlines the playbook for a decoupling of inflation and interest rates for the first time since the 1940s. This is actually a necessary policy setting to have any chance of governments solving the current debt crisis. The pathway to this outcome may not be smooth, but essentially this is the most probable scenario, given so many others (materially higher interest rates, austerity or even sovereign debt default) are far more unpalatable, with far greater social consequences.


Hence we see a problematic period ahead whereby central banks are facing the prospect of slowing economic growth, while grappling with meaningful inflation for the first time in almost 40 years. The inflation issue appears to be far stickier than most pundits had expected at the start of the year, and looks set to continue into 2022.


This challenge of unwinding the easy monetary policy settings suggests to us that uncertainty will create more volatility, and with that the desire to own a portfolio of stocks that can insulate the portfolio from significant drawdowns, while still offering strong valuation support.


We’ve made changes to our portfolio in the past quarter to find companies that will trade in a non-correlated manner to the broader market. We’re looking at a few key areas including:

  • Real assets – We believe inflation will drive real asset valuations higher.

  • Valuation margin of safety – We’re not overpaying for long-duration assets or concept stocks. Instead, we’re focused on the near-term.

  • Pricing power – We’re considering how long companies will be able to hold their prices stable before being forced to pass on inflation costs to consumers.

  • Gold – There is extreme value emerging in gold equities, as it’s the most unloved sector across global equities right now.

The current trends in markets are bringing the focus back on our core philosophies: backing ourselves when it comes to unappreciated assets, maintaining a high active share and investing in companies with strong, predictable cash flows. We seek to continue to deliver a portfolio that generates stronger alpha, with lower beta than the market.\


Disclaimer: Past performance is not a reliable indicator of future performance. Positive returns, which the Chester High Conviction Fund (the Fund) is designed to provide, are different regarding risk and investment profile to index returns. This document is for general information purposes only and does not take into account the specific investment objectives, financial situation or particular needs of any specific individual. As such, before acting on any information contained in this document, individuals should consider whether the information is suitable for their needs. This may involve seeking advice from a qualified financial adviser. Copia Investment Partners Ltd (AFSL 229316, ABN 22 092 872 056) (Copia) is the issuer of the Chester High Conviction Fund. A current PDS is available from Copia located at Level 25, 360 Collins Street, Melbourne Vic 3000, by visiting chesteram.com.au or by calling 1800 442 129 (free call). A person should consider the PDS before deciding whether to acquire or continue to hold an interest in the Fund. Any opinions or recommendations contained in this document are subject to change without notice and Copia is under no obligation to update or keep any information contained in this document current

LINKS

Small-white-transparent.png
Copia-for-web-White.png

CHESTER ASSET MANAGEMENT

Head Office

Level 47, 80 Collins Street (North Tower)
Melbourne VIC 3000

P  1800 442 129

E  clientservices@copiapartners.com.au

DISCLAIMER

 

This website provides information to help investors and their advisers assess the merits of investing in financial products. We strongly advise investors and their advisers to read information memoranda and product disclosure statements carefully. The information on this website does not constitute personal advice and does not take into account your investment objectives, financial situation or needs. It is therefore important that if you are considering investing in any financial products and services referred to on this website, you determine whether the relevant investment is suitable for your needs, objectives and financial circumstances. You should also consider seeking independent financial advice, particularly on taxation, retirement planning and investment risk tolerance before making an investment decision.

Neither Copia Investment Partners Limited, nor any of our associates, guarantee or underwrite the success of any investments, the achievement of investment objectives, the repayment of capital or payment of particular rates of return on investments. Copia Investment Partners Limited publishes information on the website that to the best of its knowledge is current at the time and is not liable for any direct or indirect losses attributable to omissions from the website, information being out of date, inaccurate, incomplete or deficient in any other way. Investors and their advisers should make their own enquiries before making investment decisions.

© 2024 Chester Asset Management | In partnership with Copia

The rating issued October 2024 APIR OPS7755AU is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2022 Lonsec. All rights reserved.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) (“Zenith”) rating (assigned APIR OPS7755AU June 2021) referred to in this piece is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at http://www.zenithpartners.com.au/RegulatoryGuidelines

bottom of page